Table S1 | Human patient samples analyzed for Axl staining. Thirty-one female TNBC patients were selected on the criteria that they displayed a residual disease after neoadjuvant treatment. The Residual Cancer Burden (RCB) index (I-II-III) after neoadjuvant treatment is associated with risk for relapse and mortality (higher is the number, higher is the risk). For each patient, the percentage of Axl-positive tumor cells in contact to the stroma is mentioned. ND, not determined. (Right) cells during random migration, three days after transfection with CTRL, AXL9 or AXL10 siRNA obtained from 110, 100 and 113 cells in 3 independent experiments for Hs578t (*p = 0.049, **p = 0.0017) and from 121, 93 and 97 cells in 3 independent experiments for MDA-MB-231, respectively (*p = 0.011 -0.019). (C) Cell survival (CelltiterGlo Assay) 72h and 144h post-transfection with CTRL, AXL9 and AXL10 siRNA. (D) Evaluation of the directionality of MDA-MB-231 cells three days after transfection with CTRL, AXL9 and AXL10 siRNA obtained from respectively 155, 123 and 126 cells in 4 independent experiments (*p = 0.018 -0.013). (E) MDA-MB-231 cells were cultured with serum and treated with DMSO (CTRL) or various concentrations (0.25, 0.5, 1 or 2 µM) of R428 for 6 h. Basal phosphorylated active AXL was then detected by western blotting using an anti-phosphotyrosine antibody after AXL immunoprecipitation. As a negative control, IgG instead of AXL antibodies were used with cells treated with DMSO. (F) Speed of Hs578t (Left) and MDA-MB-231 (Right) cells during random migration after treatment with DMSO (CTRL) or various concentrations (0.25, 0.5, 1 or 2 µM) of R428 obtained from respectively 129, 124, 125 ,110 and 99 cells in 4 independent experiments for the Hs578t (ns > 0.05, *p = 0.0117, **p = 0.0012 -0.0012 ) and from 106, 116, 104, 127 and 85 cells in 3 independent experiments for the MDA-MB-231 (*p = 0.039 -0.013, **p = 0.0062 -0.0066). (G) Migration directionality of MDA-MB-231 cells treated with DMSO (CTRL) or various concentrations (0.5, 1 or 2 µM) of R428 obtained from respectively 143, 127, 153 and 114 cells in 4 independent experiments (ns > 0.05, *p = 0.015). All graphs represent mean ± s.d. three independent experiments, respectively (ns > 0.5, *p = 0.025 -0.049 -0.012). (C) AXL intensity at the lateral area of Hs578t cells treated with DMSO (CTRL) or various concentrations (0.5, 1 or 2 µM) of R428 during 2 hours obtained from 39, 31, 26 and 39 cells in three independent experiments, respectively (*p = 0.019 -0.010 -0.041). (D) AXL intensity at the lateral area of Hs578t cells treated with DMSO (CTRL) or with 2 µM R428 during 30 min, 1h, 2h or 4h obtained from 38, 30, 32, 38 and 34 cells in three independent experiments, respectively (*p = 0.016 -0.043 -0.036, **p = 0.0055). (E) AXL intensity at the front, lateral area and rear of Hs578t cells treated with 2 µM R428 during 2h obtained from 37 cells in three independent experiments (ns > 0.05, *p = 0.010). 
